TENAX THERAPEUTICS, INC. Increase (Decrease) in Accounts Receivable and Other Operating Assets
TENAX THERAPEUTICS, INC. (TENX) reported Increase (Decrease) in Accounts Receivable and Other Operating Assets of -$1.22 million for the 3-month period ending 2025-03-31, per its 10-Q filed 2025-05-14.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInAccountsReceivableAndOtherOperatingAssets · last filed 2025-05-14
- TENAX THERAPEUTICS, INC. increase (decrease) in accounts receivable and other operating assets for the quarter ending 2025-03-31 was -$1.22M, a 6900.00% decline year-over-year.
- TENAX THERAPEUTICS, INC. increase (decrease) in accounts receivable and other operating assets for the quarter ending 2024-12-31 was $360.67K.
- TENAX THERAPEUTICS, INC. increase (decrease) in accounts receivable and other operating assets for the quarter ending 2024-09-30 was $240.93K, a 69.21% decline year-over-year.
- TENAX THERAPEUTICS, INC. increase (decrease) in accounts receivable and other operating assets for the quarter ending 2024-06-30 was -$677.60K.
- TENAX THERAPEUTICS, INC. increase (decrease) in accounts receivable and other operating assets for fiscal 2024 was -$58.00K, a 118.95% decline from fiscal 2023.
- TENAX THERAPEUTICS, INC. increase (decrease) in accounts receivable and other operating assets for fiscal 2023 was $306.00K, a 14.17% decline from fiscal 2022.
- TENAX THERAPEUTICS, INC. increase (decrease) in accounts receivable and other operating assets for fiscal 2022 was $356.52K.
| Period end | Increase (Decrease) in Accounts Receivable and Other Operating Assets 3 month | Increase (Decrease) in Accounts Receivable and Other Operating Assets 3 month as first filed | Increase (Decrease) in Accounts Receivable and Other Operating Assets 6 month | Increase (Decrease) in Accounts Receivable and Other Operating Assets 9 month | Increase (Decrease) in Accounts Receivable and Other Operating Assets 12 month | Increase (Decrease) in Accounts Receivable and Other Operating Assets 12 month as first filed |
|---|---|---|---|---|---|---|
| 2025-03-31 | -$1.22M 10-Q · filed 2025-05-14 | -$863.33K derived: sum of 2 quarters · filed 2025-05-14 | -$622.40K derived: sum of 3 quarters · filed 2025-05-14 | -$1.30M derived: sum of 4 quarters · filed 2025-05-14 | ||
| 2024-12-31 | $360.67K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-25 | $601.60K derived: sum of 2 quarters · filed 2025-03-25 | -$76.00K derived: sum of 3 quarters · filed 2025-03-25 | -$58.00K 10-K · filed 2025-03-25 | ||
| 2024-09-30 | $240.93K derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-13 | -$436.67K derived: sum of 2 quarters · filed 2024-11-13 | -$418.67K 10-Q · filed 2024-11-13 | -$455.50K derived: sum of 4 quarters · filed 2025-05-14 | ||
| 2024-06-30 | -$677.60K derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-13 | -$659.60K 10-Q · filed 2024-08-13 | -$696.43K derived: sum of 3 quarters · filed 2025-05-14 | $86.05K derived: sum of 4 quarters · filed 2025-05-14 | ||
| 2024-03-31 | $18.00K 10-Q · filed 2025-05-14 | $18.29K 10-Q · filed 2024-05-14 | -$18.83K derived: sum of 2 quarters · filed 2025-05-14 | $763.65K derived: sum of 3 quarters · filed 2025-05-14 | $558.80K derived: sum of 4 quarters · filed 2025-05-14 | |
| 2023-12-31 | -$36.83K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-25 | $745.65K derived: sum of 2 quarters · filed 2025-03-25 | $540.80K derived: sum of 3 quarters · filed 2025-03-25 | $306.00K 10-K · filed 2025-03-25 | $305.69K 10-K · filed 2024-03-28 | |
| 2023-09-30 | $782.48K derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-13 | $577.64K derived: sum of 2 quarters · filed 2024-11-13 | $342.83K 10-Q · filed 2024-11-13 | $1.31M derived: sum of 4 quarters · filed 2024-11-13 | ||
| 2023-06-30 | -$204.85K derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-13 | -$439.65K 10-Q · filed 2024-08-13 | $523.43K derived: sum of 3 quarters · filed 2024-08-13 | -$854.48K derived: sum of 4 quarters · filed 2024-08-13 | ||
| 2023-03-31 | -$234.80K 10-Q · filed 2024-05-14 | $728.28K derived: sum of 2 quarters · filed 2024-05-14 | -$649.64K derived: sum of 3 quarters · filed 2024-05-14 | |||
| 2022-12-31 | $963.08K derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-28 | -$414.83K derived: sum of 2 quarters · filed 2024-03-28 | $356.52K 10-K · filed 2024-03-28 | |||
| 2022-09-30 | -$1.38M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-13 | -$606.56K 10-Q · filed 2023-11-13 | ||||
| 2022-06-30 | $771.36K 10-Q · filed 2023-08-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| PLIANT THERAPEUTICS, INC. (PLRX) | United States | $0.071B | -0.76 |
| PMV Pharmaceuticals, Inc. (PMVP) | United States | $0.071B | -0.95 |
| Yarrow Bioscience, Inc. (YARW) | United States | $0.070B | |
| Lunai Bioworks Inc. (LNAI) | United States | $0.072B | -0.11 |
| Spero Therapeutics, Inc. (SPRO) | United States | $0.073B | 17.41 |
| Connect Biopharma Holdings Ltd (CNTB) | $0.069B | -2.17 | |
| Cingulate Inc. (CING) | United States | $0.073B | -2.64 |
| Aldeyra Therapeutics, Inc. (ALDX) | United States | $0.074B | -5.57 |
| XBiotech Inc. (XBIT) | United States | $0.066B | -1.56 |
| OS Therapies Inc (OSTX) | United States | $0.076B | -2.17 |